JNM CE/SAM (November 2017): Current Concepts in 68Ga-DOTATATE Imaging of Neuroendocrine Neoplasms: Interpretation, Biodistribution, Dosimetry, and Molecular Strategies

JNM, November 2017, Volume 58, Number 11

Release Date: 11/1/2017
Expiration Date: 11/30/2020

SNMMI Members: Free
Non-Members: $69.00

Continuing Education Credit Information

ABNM SAM Credit
The American Board of Nuclear Medicine has reviewed and approved this Journal SAM activity submitted by the SNMMI. This activity fulfills the requirements of the ABNM Maintenance of Certification program for self-assessment. 2.0 SAMs have been awarded for this activity.

AMA-PRA (Physician)
The Society for Nuclear Medicine and Medical Imaging, Inc. (SNMMI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. SNMMI designates this enduring material for a maximum of 2.0 AMA PRA Category 1 CreditsTM. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Objectives
On successful completion of this activity, participants should be able to describe…
1. The role of 68Ga-DOTATATE in neuroendocrine tumor management.
2. The interpretation of 68Ga-DOTATATE PET/CT images.
3. The integration of 68Ga-DOTATATE PET/CT in the diagnostic and management algorithm for neuroendocrine tumors.


Target Audience
This article contains information of value to nuclear medicine physicians, endocrinologists, and oncologists as well as to nuclear medicine technologists.

Authors
Lisa Bodei1, Valentina Ambrosini2, Ken Herrmann3,4, and Irvin Modlin5

1Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York; 2Nuclear Medicine, Department of Experimental Diagnostic and Specialized Medicine, University of Bologna and S. Orsola-Malpighi Hospital, Bologna, Italy; 3Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California; 4Klinik für Nuklearmedizin, Universitätsklinikum Essen, Essen, Germany; and 5Yale University School of Medicine, Department of Surgery, New Haven, Connecticut

Disclosure
Dr. Bodei is a consultant/advisor for Ipsen and AAA Pharmaceutical, and Dr. Herrmann is a consultant/advisor for Ipsen, Curium, and Sofie Biosciences and an investigator for AAA Pharmaceutical. In accordance with ACCME Revised Standards for Commercial Support and SNMMI Conflict-of-Interest Policy, the authors have indicated no other relevant relationships that could be perceived as a real or apparent conflict of interest. Disclosure of a relationship is not intended to suggest or to condone bias but is made to provide participants with information that might be of potential importance to their evaluation of the activity.


Contact Information
For questions please contact Lisa Dickinson, Associate Director of Education at ldickinson@snmmi.org or 703-652-6783.